hydron;2-[3-[[4-[(3-nitroacridin-9-yl)amino]phenyl]sulfamoyl]propyl]guanidine;chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: hydron;2-[3-[[4-[(3-nitroacridin-9-yl)amino]phenyl]sulfamoyl]propyl]guanidine;chloride
• 化学式: C23H24ClN7O4S
• 分子量: 530.0
• InChiKey: OPSGDYHBXKMPNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.56
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  190
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• [EN] COMPOSITIONS AND THEIR USES FOR TREATING CANCERS<br/>[FR] COMPOSITIONS ET LEURS UTILISATIONS POUR LE TRAITEMENT DE CANCERS
  申请人：INST NAT SANTE RECH MED

  公开号：WO2021105761A1

  公开（公告）日：2021-06-03

  The present invention relates to the field of oncology, and in particular to chemoresistant or potentially chemoresistant cancer diseases. The invention relates to a combination comprising at least one anticancer G-quadruplex ligand (G4 ligand), such as triarylpyridine 20A or quarfloxin, and at least one lysosomotropic agent, such as chloroquine or Lys05. Such combinations promote a significant induction of lysosomal membrane permeabilization (LMP) as compared to a single drug treatment and trigger massive cancer cell death. The observed synergistic effect has advantageous application in the prevention and/or treatment of chemoresistant cancer.